Cargando…
The IL-17A/IL-17RA Axis Is Not Related to Overall Survival and Cancer Stem Cell Modulation in Pancreatic Cancer
(1) Background: IL-17A accelerates pancreatic intraepithelial neoplasia (PanIN) progression. In this study, we examined whether IL-17A/IL-17RA promotes pancreatic ductal adenocarcinoma (PDAC) aggressiveness in terms of survival and cancer stem cell modulation. (2) Methods: In vitro, the wound-healin...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139783/ https://www.ncbi.nlm.nih.gov/pubmed/32210079 http://dx.doi.org/10.3390/ijms21062215 |
_version_ | 1783518846086283264 |
---|---|
author | Li, Jiahui Betzler, Christopher Lohneis, Philipp Popp, Marie Christine Qin, Jiwei Kalinski, Thomas Wartmann, Thomas Bruns, Christiane J. Zhao, Yue Popp, Felix C. |
author_facet | Li, Jiahui Betzler, Christopher Lohneis, Philipp Popp, Marie Christine Qin, Jiwei Kalinski, Thomas Wartmann, Thomas Bruns, Christiane J. Zhao, Yue Popp, Felix C. |
author_sort | Li, Jiahui |
collection | PubMed |
description | (1) Background: IL-17A accelerates pancreatic intraepithelial neoplasia (PanIN) progression. In this study, we examined whether IL-17A/IL-17RA promotes pancreatic ductal adenocarcinoma (PDAC) aggressiveness in terms of survival and cancer stem cell modulation. (2) Methods: In vitro, the wound-healing assay, the sphere formation assay, and flow cytometry were applied to assess cancer stem cell features. In vivo, pancreatic tumors were induced in C57BL/6 mice using electroporation with oncogenic plasmids (P53-/- R172H; KrasG12V). Anti-IL-17 antibodies were administered as immunotherapy. We analyzed IL-17A/IL-17RA related survival using publicly available transcriptomic data (n = 903). (3) Results: IL-17A/IL-17RA expression was not related to survival in PDAC patients. IL-17A neither induces stem cell markers nor increases sphere formation and cell motility in vitro. Blocking the IL-17A/IL-17RA axis in a murine pancreatic cancer model did not improve the survival of mice, but reduced the tumor burden slightly. (4) Conclusions: IL-17A does not promote stem cell expansion in PDAC cell lines. Blocking IL-17A/IL-17RA signaling does not interfere with pancreatic cancer development and progression and may not be considered as a promising monotherapy for PDAC. |
format | Online Article Text |
id | pubmed-7139783 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71397832020-04-10 The IL-17A/IL-17RA Axis Is Not Related to Overall Survival and Cancer Stem Cell Modulation in Pancreatic Cancer Li, Jiahui Betzler, Christopher Lohneis, Philipp Popp, Marie Christine Qin, Jiwei Kalinski, Thomas Wartmann, Thomas Bruns, Christiane J. Zhao, Yue Popp, Felix C. Int J Mol Sci Communication (1) Background: IL-17A accelerates pancreatic intraepithelial neoplasia (PanIN) progression. In this study, we examined whether IL-17A/IL-17RA promotes pancreatic ductal adenocarcinoma (PDAC) aggressiveness in terms of survival and cancer stem cell modulation. (2) Methods: In vitro, the wound-healing assay, the sphere formation assay, and flow cytometry were applied to assess cancer stem cell features. In vivo, pancreatic tumors were induced in C57BL/6 mice using electroporation with oncogenic plasmids (P53-/- R172H; KrasG12V). Anti-IL-17 antibodies were administered as immunotherapy. We analyzed IL-17A/IL-17RA related survival using publicly available transcriptomic data (n = 903). (3) Results: IL-17A/IL-17RA expression was not related to survival in PDAC patients. IL-17A neither induces stem cell markers nor increases sphere formation and cell motility in vitro. Blocking the IL-17A/IL-17RA axis in a murine pancreatic cancer model did not improve the survival of mice, but reduced the tumor burden slightly. (4) Conclusions: IL-17A does not promote stem cell expansion in PDAC cell lines. Blocking IL-17A/IL-17RA signaling does not interfere with pancreatic cancer development and progression and may not be considered as a promising monotherapy for PDAC. MDPI 2020-03-23 /pmc/articles/PMC7139783/ /pubmed/32210079 http://dx.doi.org/10.3390/ijms21062215 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Li, Jiahui Betzler, Christopher Lohneis, Philipp Popp, Marie Christine Qin, Jiwei Kalinski, Thomas Wartmann, Thomas Bruns, Christiane J. Zhao, Yue Popp, Felix C. The IL-17A/IL-17RA Axis Is Not Related to Overall Survival and Cancer Stem Cell Modulation in Pancreatic Cancer |
title | The IL-17A/IL-17RA Axis Is Not Related to Overall Survival and Cancer Stem Cell Modulation in Pancreatic Cancer |
title_full | The IL-17A/IL-17RA Axis Is Not Related to Overall Survival and Cancer Stem Cell Modulation in Pancreatic Cancer |
title_fullStr | The IL-17A/IL-17RA Axis Is Not Related to Overall Survival and Cancer Stem Cell Modulation in Pancreatic Cancer |
title_full_unstemmed | The IL-17A/IL-17RA Axis Is Not Related to Overall Survival and Cancer Stem Cell Modulation in Pancreatic Cancer |
title_short | The IL-17A/IL-17RA Axis Is Not Related to Overall Survival and Cancer Stem Cell Modulation in Pancreatic Cancer |
title_sort | il-17a/il-17ra axis is not related to overall survival and cancer stem cell modulation in pancreatic cancer |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139783/ https://www.ncbi.nlm.nih.gov/pubmed/32210079 http://dx.doi.org/10.3390/ijms21062215 |
work_keys_str_mv | AT lijiahui theil17ail17raaxisisnotrelatedtooverallsurvivalandcancerstemcellmodulationinpancreaticcancer AT betzlerchristopher theil17ail17raaxisisnotrelatedtooverallsurvivalandcancerstemcellmodulationinpancreaticcancer AT lohneisphilipp theil17ail17raaxisisnotrelatedtooverallsurvivalandcancerstemcellmodulationinpancreaticcancer AT poppmariechristine theil17ail17raaxisisnotrelatedtooverallsurvivalandcancerstemcellmodulationinpancreaticcancer AT qinjiwei theil17ail17raaxisisnotrelatedtooverallsurvivalandcancerstemcellmodulationinpancreaticcancer AT kalinskithomas theil17ail17raaxisisnotrelatedtooverallsurvivalandcancerstemcellmodulationinpancreaticcancer AT wartmannthomas theil17ail17raaxisisnotrelatedtooverallsurvivalandcancerstemcellmodulationinpancreaticcancer AT brunschristianej theil17ail17raaxisisnotrelatedtooverallsurvivalandcancerstemcellmodulationinpancreaticcancer AT zhaoyue theil17ail17raaxisisnotrelatedtooverallsurvivalandcancerstemcellmodulationinpancreaticcancer AT poppfelixc theil17ail17raaxisisnotrelatedtooverallsurvivalandcancerstemcellmodulationinpancreaticcancer AT lijiahui il17ail17raaxisisnotrelatedtooverallsurvivalandcancerstemcellmodulationinpancreaticcancer AT betzlerchristopher il17ail17raaxisisnotrelatedtooverallsurvivalandcancerstemcellmodulationinpancreaticcancer AT lohneisphilipp il17ail17raaxisisnotrelatedtooverallsurvivalandcancerstemcellmodulationinpancreaticcancer AT poppmariechristine il17ail17raaxisisnotrelatedtooverallsurvivalandcancerstemcellmodulationinpancreaticcancer AT qinjiwei il17ail17raaxisisnotrelatedtooverallsurvivalandcancerstemcellmodulationinpancreaticcancer AT kalinskithomas il17ail17raaxisisnotrelatedtooverallsurvivalandcancerstemcellmodulationinpancreaticcancer AT wartmannthomas il17ail17raaxisisnotrelatedtooverallsurvivalandcancerstemcellmodulationinpancreaticcancer AT brunschristianej il17ail17raaxisisnotrelatedtooverallsurvivalandcancerstemcellmodulationinpancreaticcancer AT zhaoyue il17ail17raaxisisnotrelatedtooverallsurvivalandcancerstemcellmodulationinpancreaticcancer AT poppfelixc il17ail17raaxisisnotrelatedtooverallsurvivalandcancerstemcellmodulationinpancreaticcancer |